Ufenau Capital Partners acquires a majority stake in Dr. Niedermaier Pharma Group
28 July 2022 – Ufenau Capital Partners acquires a majority stake in Dr. Niedermaier Pharma Group, a leading producer and supplier of organic nutritional supplements and natural cosmetics with headquarters in Hohenbrunn near Munich (Germany) and in Appenzell with over 50 employees, an innovative research team and various cooperation partners.
Founded 1939, Dr. Niedermaier Pharma Group produces and distributes across Europe nutritional supplements, natural cosmetics and beauty liquids in the premium segment based on the patented "Regulatessence". "Regulatessence" is a highly concentrated, plant-based enzyme digest.
Together with Ufenau, the strong market position of Dr. Niedermaier Pharma Group will be expanded through strategic acquisitions, extension of the product portfolio and geographical reach. As part of the transaction, the former shareholders and managers will reinvest in the newly formed group, NZYM AG, and will continue their successful engagement at Dr. Niedermaier Pharma Group.
Walder Wyss advised Ufenau Capital Partners on the transaction. The team was led by Stefan Knobloch (Corporate/M&A, Partner) and Fabienne Anner (Corporate/M&A, Managing Associate) and further included Letizia Schlegel (Corporate/M&A, Associate), Christine Leuch (IP/IT, Managing Associate) and Valentina Eichin (Employment, Associate).